Houston data science company expands pandemic-inspired research tool

by the numbers

Mercury Data Science has taken a tool it originally developed for COVID-19 research and applied it into new areas of research and innovation. Photo via Getty Images

Last fall, Houston-based Mercury Data Science released an AI-driven app designed to help researchers unlock COVID-19-related information tucked into biomedical literature. The app simplified access to data about subjects like genes, proteins, drugs, and diseases.

Now, a year into the coronavirus pandemic, Mercury Data Science is applying this technology to areas like agricultural biotech, cancer therapeutics, and neuroscience. It's an innovation that arose from the pandemic but that promises broader, long-lasting benefits.

Angela Holmes, chief operating officer of Mercury Data Science, says the platform relies on an AI concept known as natural language processing (NLP) to mine scientific literature and deliver real-time results to researchers.

"We developed this NLP platform as a publicly available app to enable scientists to efficiently discover biological relationships contained in COVID research publications," Holmes says.

The platform:

  • Contains dictionaries with synonyms to identify things like genes and proteins that may go by various names in scientific literature.
  • Produces data visualizations of relationships among various biological functions.
  • Summarizes the most important data points on a given topic from an array of publications.
  • Depends on data architecture to automate how data is retrieved and processed.

In agricultural biotech, the platform enables researchers to sift through literature to dig up data about plant genetics, Holmes says. The lack of gene-naming standards in the world of plants complicates efforts to search data about plant genetics, she says.


Angela Holmes is the COO of MDS. Photo via mercuryds.com


The platform's ability to easily ferret out information about plant genetics "allows companies seeking gene-editing targets to make crops more nutritious and more sustainable as the climate changes to have a rapid way to de-risk their genomic analyses by quickly assessing what is already known versus what is unknown," Holmes says.

The platform allowed one of Mercury Data Science's agricultural biotech customers to comb through scientific literature about plant genetics to support targeted gene editing in a bid to improve crop yields.

In the field of cancer therapeutics and other areas of pharmaceuticals, the platform helps prioritize drug candidates, Holmes says. One of Mercury Data Science's customers used the platform to extract data from about 2 terabytes (or 2 trillion bytes) of information to evaluate drug candidates. The information included drug studies, clinical trials, and patents. Armed with that data, Mercury Data Science's cancer therapy client signed agreements with new pharmaceutical partners.

The platform also applies to the hunt for biomarkers in neuroscience, including disorders such as depression, anxiety, autism and multiple sclerosis. Data delivered through the platform helps bring new neurobehavioral therapeutics to market, Holmes says.

"An NLP platform to automatically process newly published literature for more insight on the search for digital biomarkers represents a great opportunity to accelerate research in this area," she says.

Mercury Data Science has experience in the field of digital biomarkers, including work for one customer to develop a voice and video platform to improve insights into patients with depression and anxiety in order to improve treatment of those conditions.

The new platform — initially developed as a tool to combat COVID-19 — falls under the startup's vast umbrella of artificial intelligence and data science. Founded in 2017, Mercury Data Science emerged because portfolio companies of the Houston-based Mercury Fund were seeking to get a better handle on AI and data science.

Last April, Angela Wilkins, founder, co-CEO and chief technology officer of Mercury Data Science, left the company to lead Rice University's Ken Kennedy Institute. Dan Watkins, co-founder and managing director of the Mercury Fund, remains at Mercury Data Science as CEO.

The Ken Kennedy Institute fosters collaborations in computing and data. Wilkins replaced Jan Odegard as executive director of the institute. Odegard now is senior director of industry and academic partnerships at The Ion, the Rice-led innovation hub.

Wilkins "is an academic at heart with considerable experience working with faculty and students, and an entrepreneur who has helped build a successful technology company," Lydia Kavraki, director of the Ken Kennedy Institute, said in a news release announcing Wilkins' new role. "Over her career, Angela has worked on data and computing problems in a number of disciplines, including engineering, life sciences, health care, agriculture, policy, technology, and energy."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston space tech co. lands $175M and more innovation news to know

Trending News

Editor's note: The top Houston innovation news for the month includes major fundraising rounds for two Houston scaleups and local inductees into the National Academy of Inventors. Here are the five most-read InnovationMap headlines from March 1-15, 2026:

1. Intuitive Machines secures $175M equity investment to fuel growth

Intuitive Machines has landed a $175 million investment as it looks secure satellite deals and develop space-based data centers. Photo courtesy Intuitive Machines.

Houston-based space infrastructure and services company Intuitive Machines has secured a $175 million equity investment from unidentified institutional investors. The investors received shares of Class A stock in exchange for their funding. Publicly held Intuitive Machines (Nasdaq: LUNR) says it plans to use the capital to help build revenue and invest in technology, including communications and data-processing networks. Continue reading.

2. Houston e-commerce giant Cart.com raises $180M, surpasses $1B in funding

Cart.com has raised $180 million to scale its logistics network, expand AI capabilities and develop workflow automation tools. Photo courtesy of Cart.com

Houston-based commerce and logistics platform Cart.com has raised $180 million in growth capital from private equity firm Springcoast Partners, pushing the startup past the $1 billion funding mark since its founding in 2020. Cart.com says it will use the capital to scale its logistics network, expand AI capabilities and develop workflow automation tools. Continue reading.

3. Houston leads Texas with 7 new National Academy of Inventors senior members

The University of Houston has more faculty named to this year’s senior member class of the National Academy of Inventors than any other Texas institution. Photos courtesy UH.

The University of Houston is now home to seven new senior members of the National Academy of Inventors. According to UH, its seven new members represent the largest group from any single Texas institution this year, bringing the university's total senior member count to 46. Continue reading.

4. Booming Houston suburb launches innovation grant to attract startups

The City of Sugar Land is putting money on the table to support startups that relocate jobs to southwest Houston. Photo via Getty Images.

Think you’ve got a burgeoning startup? Consider moving it to southwest Houston. The City of Sugar Land announced the Sugar Land Starts Innovation Fund to support companies that move jobs to the area. Continue reading.

5. 6+ can't-miss Houston business and innovation events in March

From CERAWeek to H-Town Roundup, here's what not to miss this month and how to register. Photo courtesy of CERAWeek

March brings the return of some of Houston’s signature innovation events, plus insightful talks and celebrations in honor of Women's History Month. Here’s what not to miss and how to register. Continue reading.

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

View All Listings